Discover DURECT's Q4 2024 earnings insights, progress on larsucosterol's Phase 3 trial for alcohol-associated hepatitis, and strategies to secure funding.

Fintel reports that on March 24, 2025, Oppenheimer initiated coverage of Quince Therapeutics (NasdaqGS:QNCX) with a ...

Discover Skye Bioscience's progress on nimacimab with early trial enrollment, extended treatment protocols, and robust regulatory plans.

Ovid Therapeutics (NASDAQ:OVID – Get Free Report) had its price objective cut by BTIG Research from $5.00 to $4.00 in a ...

Thank you for standing by and welcome to the Corvus Pharmaceuticals fourth-quarter and full-year 2024 business update and financial results conference call. (Operator Instructions) It is now my ...

Oppenheimer restated their outperform rating ... product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. Receive News & Ratings ...

Darden Restaurants reported third-quarter earnings below expectations, with sales of $3.158 billion missing the consensus ...

Dane DeHaan (“American Primeval,” “Oppenheimer)” has been tapped for a major recurring role opposite leads Callum Turner and ...

Nektar Therapeutics (NASDAQ:NKTR) operates as a biopharmaceutical company that discovers and develops therapies to treat ...

FDX shares tanked after reporting downbeat Q3 results & lower FY25 revenue forecast. Analysts maintain mixed ratings & ...

Welcome to the Amprius Technologies fourth quarter and full-year 2024 earnings conference call. Joining us for today's presentation are the company's CEO, Dr. Kang Sun; and CFO, Sandra Wallach.